After Covid-19 success, Moderna is going after an HIV vaccine

After Covid-19 success, Moderna is going after an HIV vaccine

Moderna's coronavirus disease (COVID-19) vaccine at the Bathgate Post Office vaccination facility in the Bronx, New York

Arguably the most important outcome of the  Covid-19 vaccines produced by Pfizer and Moderna isn’t ending the pandemic. Instead, it’s what the innovative mRNA technology used to make the vaccine could do next.

Vaccines using mRNA have potential uses far beyond immunization—to treat cancer, for instance, or addiction, Lynda Stuart, deputy director for vaccines at the Bill and Melinda Gates Foundation, told Quartz. But as new applications for mRNA vaccines are explored, one seems more immediate: other infectious diseases.

A glimpse of what that might look like was provided today by Moderna, the 10-year-old Cambridge, Massachusetts-based company that supplied the technology undergirding Pfizer’s vaccine. The company announced a program to develop vaccines for the seasonal flu, the Nipah virus (a virus that can cause various conditions, including encephalitis), and HIV.

How to Bolster Your Immune System

Leave a Reply

Your email address will not be published. Required fields are marked *